Targeting BCL2 in Myeloma and Predicting Response

Multiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including CAR-T therapy and T-cell engagers, are providing hope for patients, and novel targets are continuously being explored, especially in the relapsed/refractory setting.

In this exclusive podcast, leading experts Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, and Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discuss novel targets in multiple myeloma, including RAS and PIKfyve, and further comment on the epigenomics and epigenetics of resistance to proteasome inhibitors and IMiDs, as well as PROTAC therapy for difficult to manipulate targets.

The post An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs appeared first on VJHemOnc.